PolarCool AB

Equities

POLAR

SE0012570422

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
0.1255 SEK -4.92% Intraday chart for PolarCool AB +23.04% -52.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PolarCool AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
PolarCool to Offer Concussion Therapy to United Rugby Championship League's Cardiff Rugby MT
PolarCool Signs Concussion Treatment Deal with EC Klagenfurter MT
PolarCool, Neurovision Sport and Performance Sign Strategic Partnership Deal MT
PolarCool Inks Deal with Swiss Professional Ice Hockey Club for Concussion Treatment MT
PolarCool to Provide Concussion Treatment to German Ice Hockey League Team MT
PolarCool AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
PolarCool Strikes Deals with Swedish Hockey League’s Clubs for Concussion Product; Shares Drop MT
PolarCool AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
PolarCool AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PolarCool AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
PolarCool Secures Two-Year Deal With Danish Hockey Club for PolarCap; Shares Sink 11% MT
PolarCool AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
PolarCool Signs Supply Agreement with Welsh Football Federation MT
PolarCool Developed PolarCap CI
PolarCool Up 11% Amid Two-Year Deal with London Irish Rugby Team MT
PolarCool To Supply PolarCap to Ice Hockey Team Kalmar HC MT
PolarCool AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
PolarCool Drops 12% After Three-year Deal With Swedish Hockey Team MT
PolarCool AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
PolarCool AB announced that it has received SEK 0.60638 million in funding CI
PolarCool AB announced that it expects to receive SEK 0.60638 million in funding CI
PolarCool AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
PolarCool AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
PolarCool : Secures Evaluation Agreement With French Rugby Team MT
Chart PolarCool AB
More charts
Polarcool AB is a Sweden-based medical device company specializing in sports medicine. The Company focuses on of concussive and sub-concussive brain injuries. It develops a portable brain cooling device called PolarCap System. The PolarCap System consists of a cooling unit and a silicone-based cooling cap alongside neoprene insulation, cooling the head and neck via a circulating coolant during a procedure that takes approximately 45-60 minutes. The idea behind it is the reduction of brain temperature of individuals suffering from a concussion or participating in an activity where repetitive head impact occurs, such as contact and combat sports, in order to prevent or limit long term cognitive impairment. The device undergoes preclinical cohort study for concussion among hockey players and a preclinical study for indication of sub-concussive repetitive head impact among American football players.
More about the company
  1. Stock Market
  2. Equities
  3. POLAR Stock
  4. News PolarCool AB
  5. PolarCool, Neurovision Sport and Performance Sign Strategic Partnership Deal